TPO
ENSG00000115705
Target class
Enzyme
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- TPX
- Target name
- TPO
- Gene name
- Thyroid peroxidase
- Gene symbol
- TPO
- Protein name
- Thyroid peroxidase (TPO) (EC 1.11.1.8)
- Gene biotype
- Protein coding
- Gene family
- Sushi domain containing|Heme peroxidase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 22
- Highest tissue expression
- 1,180
- Tissue specificity (Gini)
- 0.961
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:7173
- Reactome pathways
- R-HSA-209968
- Protein interaction confidence
- 0.886389
- Protein interaction partners
- 18
- End position
- 1543711
- Start position
- 1373933
- Chromosome
- 2
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 3]: Cell surface.
- Tissue specificity (tau)
- 0.998502
- Expression inequality (Gini)
- 0.960759
Expression in transcripts per million
- Thyroid
- 1,180
- Spleen
- 19.92
- Adipose - Subcutaneous
- 9.7
- Breast - Mammary Tissue
- 7.81
- Esophagus - Gastroesophageal Junction
- 6.7
Expression in transcripts per million
- Thyroid1,180
- Spleen19.92
- Adipose - Subcutaneous9.7
- Breast - Mammary Tissue7.81
- Esophagus - Gastroesophageal Junction6.7
- Esophagus - Muscularis6.59
- Nerve - Tibial5.95
- Adipose - Visceral (Omentum)5.22
- Colon - Sigmoid3.39
- Heart - Left Ventricle2.68
- Small Intestine - Terminal Ileum2.46
- Colon - Transverse2.28
- Minor Salivary Gland2.22
- Artery - Coronary2.02
- Muscle - Skeletal1.87
- Testis1.63
- Bladder1.6
- Artery - Aorta1.31
- Artery - Tibial1.31
- Skin - Sun Exposed (Lower leg)1.1
- Esophagus - Mucosa1.08
- Stomach1.06
- Skin - Not Sun Exposed (Suprapubic)0.71
- Pituitary0.46
- Vagina0.43
And 29 more, listed on the interactive page.
Biological processes
- GO:0035162
- GO:0005576
- GO:0005886
Molecular functions
- GO:0004601
Increased Mortality
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceCognitive Function, Decreased
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceAltered, Amphibian metamorphosis
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceIncreased Mortality
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceDecrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence sourceIncrease, Adenomas/carcinomas (follicular cell)
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- thyroid follicle
Evidence source
Related records
Trials (47)
- A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
- A Clinical Study of Hyperthyroidism in Children
- A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
- A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
- A Study in Participants With Non-cirrhotic NASH With Fibrosis
- A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
- A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
- A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
- A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
- A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
- A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
- Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
- AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease
- An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
- Antithyroid Drug Treatment of Thyrotoxicosis in Young People
- Antithyroid Drugs During Radioiodine Therapy
- Block-replacement Therapy During Radioiodine Therapy
- Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
- Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone
- Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease
Drugs (4)
- Carbimazole Thyroid peroxidase inhibitor
- Methimazole Thyroid peroxidase inhibitor
- Mitiperstat
- Propylthiouracil Thyroid peroxidase inhibitor